×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SLDB – solid biosciences inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SLDB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/16
05:26 pm
sldb
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services [Yahoo! Finance]
Low
Report
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services [Yahoo! Finance]
12/16
04:51 pm
sldb
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
Medium
Report
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
12/8
08:00 am
sldb
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
Low
Report
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum
12/6
05:47 am
sldb
Solid Biosciences (NASDAQ:SLDB) was upgraded by analysts at Needham & Company LLC to a "moderate buy" rating.
Low
Report
Solid Biosciences (NASDAQ:SLDB) was upgraded by analysts at Needham & Company LLC to a "moderate buy" rating.
12/4
07:19 am
sldb
Solid Biosciences (NASDAQ:SLDB) is now covered by analysts at Needham & Company LLC. They set a "buy" rating on the stock.
High
Report
Solid Biosciences (NASDAQ:SLDB) is now covered by analysts at Needham & Company LLC. They set a "buy" rating on the stock.
12/1
04:05 pm
sldb
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1
08:00 am
sldb
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Medium
Report
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
11/17
08:21 am
sldb
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]
Low
Report
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/4
04:22 pm
sldb
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Howton David T
Low
Report
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Howton David T
12/4
04:21 pm
sldb
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Cumbo Alexander
Low
Report
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Cumbo Alexander
12/4
04:19 pm
sldb
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Hanrahan Jessie
Low
Report
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Hanrahan Jessie
12/4
04:17 pm
sldb
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Herzich Paul
Low
Report
Form 4 Solid Biosciences Inc. For: Dec 02 Filed by: Herzich Paul
12/3
05:07 pm
sldb
Form 144 Solid Biosciences Inc. Filed by: Cumbo Alexander
High
Report
Form 144 Solid Biosciences Inc. Filed by: Cumbo Alexander
11/13
09:08 am
sldb
Form SCHEDULE 13G/A Solid Biosciences Inc. Filed by: Adage Capital Management, L.P.
Medium
Report
Form SCHEDULE 13G/A Solid Biosciences Inc. Filed by: Adage Capital Management, L.P.
11/3
05:23 pm
sldb
Form 10-Q Solid Biosciences Inc. For: Sep 30
Medium
Report
Form 10-Q Solid Biosciences Inc. For: Sep 30
11/3
05:16 pm
sldb
Form 8-K Solid Biosciences Inc. For: Nov 03
Medium
Report
Form 8-K Solid Biosciences Inc. For: Nov 03
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/26
Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors
34.4%
8/16 Solid Biosciences Inc (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 33.5%
8/14 Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update 23.8%
5/14 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating. They now have a $7.50 price target on the stock. 18.9%
10/11 Solid Biosciences Inc (NASDAQ: SLDB) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock. 11.2%
9/20 Solid Biosciences Inc (NASDAQ: SLDB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 11.2%
10/16 SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Solid Biosciences Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors 10.7%
7/29 Form 4 Solid Biosciences Inc. For: Jul 25 Filed by: Ganot Ilan 9.0%
8/27 Solid Biosciences Looks Like An Obvious Sell [Seeking Alpha] 8.7%
11/12 Solid Biosciences Inc (NASDAQ: SLDB) had its price target lowered by analysts at Credit Suisse Group AG from $6.00 to $2.00. They now have a "hold" rating on the stock. 7.4%
8/16 Solid Biosciences Inc (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 33.5%
8/14 Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update 23.8%
5/14 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Chardan Capital from a "buy" rating to a "neutral" rating. They now have a $7.50 price target on the stock. 18.9%
10/11 Solid Biosciences Inc (NASDAQ: SLDB) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock. 11.2%
9/20 Solid Biosciences Inc (NASDAQ: SLDB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 11.2%
10/16 SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Solid Biosciences Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors 10.7%
7/29 Form 4 Solid Biosciences Inc. For: Jul 25 Filed by: Ganot Ilan 9.0%
8/27 Solid Biosciences Looks Like An Obvious Sell [Seeking Alpha] 8.7%
11/12 Solid Biosciences Inc (NASDAQ: SLDB) had its price target lowered by analysts at Credit Suisse Group AG from $6.00 to $2.00. They now have a "hold" rating on the stock. 7.4%
TOP News Decliners
11/12
Solid Biosciences Provides SGT-001 Program Update
-74.4%
5/13 Q1/2019 3/31/2019 EPS -0.850 ZacksConsensus -0.610 ActVsEst (0.240) - Miss -28.6%
3/13 Form 4 Solid Biosciences Inc. For: Mar 11 Filed by: Ziolkowski Jennifer Lynn -21.1%
12/18 Solid Biosciences stock are up on DMD study news [MarketWatch] -20.1%
1/9 Form 8-K Solid Biosciences Inc. For: Jan 07 -14.6%
3/23 Solid Biosciences Inc (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock. -9.3%
7/26 Form 8-K Solid Biosciences Inc. For: Jul 25 -9.2%
3/20 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.9%
8/29 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Citigroup Inc from a "neutral" rating to a "sell" rating. They now have a $6.00 price target on the stock. -5.4%
7/31 Form D Solid Biosciences Inc. -5.3%
5/13 Q1/2019 3/31/2019 EPS -0.850 ZacksConsensus -0.610 ActVsEst (0.240) - Miss -28.6%
3/13 Form 4 Solid Biosciences Inc. For: Mar 11 Filed by: Ziolkowski Jennifer Lynn -21.1%
12/18 Solid Biosciences stock are up on DMD study news [MarketWatch] -20.1%
1/9 Form 8-K Solid Biosciences Inc. For: Jan 07 -14.6%
3/23 Solid Biosciences Inc (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock. -9.3%
7/26 Form 8-K Solid Biosciences Inc. For: Jul 25 -9.2%
3/20 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.9%
8/29 Solid Biosciences Inc (NASDAQ: SLDB) was downgraded by analysts at Citigroup Inc from a "neutral" rating to a "sell" rating. They now have a $6.00 price target on the stock. -5.4%
7/31 Form D Solid Biosciences Inc. -5.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: